Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies

Success of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) has given patients hope for a long disease-free-survival. A longer survival raises the question of late effects, including development of another malignancy. Records of 1445 patients with CML/myeloproliferative neoplasm o...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Verma, Dushyant, Kantarjian, Hagop, Strom, Sara S., Rios, Mary Beth, Jabbour, Elias, Quintas-Cardama, Alfonso, Verstovsek, Srdan, Ravandi, Farhad, O'Brien, Susan, Cortes, Jorge
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2011
Teme:
Clinical Trials and Observations
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3291487/
https://ncbi.nlm.nih.gov/pubmed/21846902
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-06-362889
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items